SOD1 A4V

SOD1 is a critical antioxidant enzyme that converts harmful superoxide radicals into less damaging molecules, protecting motor neurons from oxidative stress. Mutations in the SOD1 gene account for approximately 2% of all ALS cases and about 20% of familial cases [2]. The A4V mutation, where alanine at position 4 is replaced by valine, is particularly significant as one of the most common SOD1 mutations in North American ALS populations and is associated with rapid disease progression, with patients typically surviving only 1-2 years after symptom onset. The AlphaFold2 prediction for SOD1 A4V achieved an exceptionally high average confidence score of 97.8 pLDDT, indicating that the computational model is highly reliable across virtually all regions of the protein structure. This high confidence allows for meaningful structural interpretation of how the A4V mutation affects the protein. Position 4 is located near the N-terminus of SOD1, a region critical for protein folding and stability. The substitution of the small, non-branched alanine with the larger, branched valine at this early position likely disrupts normal protein folding pathways and destabilizes the native structure, even though the mutation does not directly involve the enzyme's active site. The mechanism by which SOD1 mutations cause ALS involves a toxic gain-of-function rather than simple loss of enzymatic activity. Mutant SOD1 proteins, including A4V, tend to misfold and form toxic aggregates that accumulate in motor neurons [4]. These aggregates can interact with other ALS-associated proteins, as recent studies have shown that glycated SOD1 modulates levels of phosphorylated TDP-43, another hallmark protein in ALS pathology [1]. The A4V mutation's location near the N-terminus may particularly favor early misfolding events that initiate aggregation cascades. Therapeutic strategies like tofersen, an antisense oligonucleotide designed to reduce mutant SOD1 protein synthesis through targeted mRNA degradation, have shown promise in treating SOD1-associated ALS [4]. While most SOD1 mutations present with predominant lower motor neuron symptoms, the phenotypic spectrum can vary considerably [3]. The high structural confidence of the A4V prediction provides a robust foundation for understanding mutation-specific effects and could inform development of targeted therapies. The mutation's consistent association with rapid progression and its high prevalence in certain populations make it a priority target for both mechanistic studies and therapeutic intervention [2]. Understanding the structural consequences of mutations like A4V at atomic resolution remains essential for developing effective treatments for this devastating disease.